A study to assess impact of blood-based biomarkers on survival outcomes on treatment with Pembrolizumab in advanced non-small cell lung cancer patients
Latest Information Update: 06 Oct 2020
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Brain metastases; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Oct 2020 New trial record
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress